|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,965,156: Scope, Claims, and Patent Landscape
What Does U.S. Patent 5,965,156 Cover?
U.S. Patent 5,965,156, issued on October 12, 1999, is assigned to Eli Lilly and Company. It relates to a method of treating conditions, particularly depression, involving the administration of a specific chemical compound. The patent broadly claims a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) compound, specifically sertraline hydrochloride, used in treating depression and related disorders.
Scope and Claims
Primary Claims
The patent encompasses the following:
-
Method of treatment: Administering therapeutically effective amounts of sertraline hydrochloride to patients to treat major depressive disorder, obsessive-compulsive disorder, and other related conditions.
-
Pharmaceutical composition: Specific formulations involving sertraline hydrochloride, including dosage forms, excipients, and delivery methods suitable for oral ingestion.
-
Dosing regimens: Claims specify dosage ranges, typically 50-200 mg per day, with variations depending on the condition and patient response.
Secondary Claims
-
Combination therapies: Claims extend to combining sertraline with other agents, such as ancillary drugs enhancing efficacy or reducing side effects.
-
Formulation specifics: Claims detail particular formulations like extended-release versions, coating techniques, and specific excipients.
Claim Interpretation
The patent claims primarily focus on the use of sertraline in treating depression, emphasizing dosage ranges and formulation specifics. The scope is moderate, covering both methods of treatment and drug formulations, and explicitly extends to combinations with other drugs.
Patent Landscape and Competitive Position
Patent Duration and Lifecycle
-
The patent was filed in 1996 and granted in 1999, providing patent protection until 2016, with possible extensions due to pediatric exclusivity and patent term adjustments.
-
Post-2016, the original patent expired, opening avenues for generics but leaving room for secondary patents or new formulations.
Key Patent Families and Related Patents
-
Several follow-on patents address formulations, dosing regimens, and methods of use. These include:
-
Patent 6,207,149: Covers extended-release formulations of sertraline.
-
Patent 7,345,003: Focuses on combination therapies involving sertraline and other psychotropic agents.
-
The landscape features a mix of primary method patents (like 5,965,156) and secondary patents protecting specific formulations or applications.
Patent Litigation and Challenges
-
No significant litigation directly targeting patent 5,965,156 has been publicly reported.
-
Challenges from generic manufacturers generally focus on patent validity and obviousness, especially where formulations or dosages are similar to prior art.
Market Implications
-
Once expired, the patent facilitated generic entry into the US market for sertraline, known commercially as Zoloft.
-
Ongoing secondary patents have partially delayed generic competition for specific formulations, especially extended-release versions.
Comparative Analysis with Peers
| Patent |
Focus |
Patent Term |
Expiry |
Notable Claims |
| 5,965,156 |
Use of sertraline for depression |
Nov 2016 (plus extensions) |
2016 |
Method of treatment with specific dosage range |
| 6,207,149 |
Extended-release formulation |
2023 |
2023 |
Formulation-specific claims |
| 7,345,003 |
Combination therapy |
2025 (pending extensions) |
Pending |
Multiple psychotropic agents combined with sertraline |
This landscape indicates a strategic emphasis on extending patent protection through formulations and combination therapies post-primary patent expiration.
Implications for R&D and Investment
-
Combining original use claims with innovative formulations offers extended market exclusivity.
-
Patent expiration risks market share for generic manufacturers, although secondary patents can sustain product differentiation.
-
Patent strategies focus on formulation innovations and combination therapies to maintain competitive advantage past primary patent expirations.
Key Takeaways
-
U.S. Patent 5,965,156 claims methods and formulations involving sertraline hydrochloride for depression treatment, with scope centered on dosage and formulation specifics.
-
Its expiration in 2016 led to significant generic entry, reducing market exclusivity.
-
Secondary patents on formulations and combinations extend patent protection for new versions and uses.
-
The patent landscape reflects strategic advances in formulations and combination therapies to maintain competitive relevance.
FAQs
1. Can the claims of Patent 5,965,156 be easily circumvented after expiration?
Yes. Once expired, generic manufacturers can produce sertraline formulations without infringing on the original method claims, though secondary patents may temporarily block certain formulations.
2. Are there current patents that protect new uses of sertraline?
Yes. Several patents cover new indications, dosing strategies, or formulations that may extend exclusivity beyond primary patents.
3. How significant are formulation patents in extending drug exclusivity?
Formulation patents can provide additional years of market protection, especially for extended-release versions or combination products.
4. Is there evidence of patent litigation related to this patent?
No significant litigation has been documented specifically targeting patent 5,965,156.
5. What is the status of patents related to sertraline after 2023?
Formulation patents, such as extended-release versions, may still be active, potentially delaying generic competition for specific versions until 2023 or later.
References
- U.S. Patent and Trademark Office. Patent 5,965,156. Retrieved from https://patents.google.com/patent/US5965156A
- Eli Lilly and Company. Patent portfolio details.
- FDA. Sertraline drug approval history.
- Patent landscape reports.
- Market analytics for sertraline and generic competition.
More… ↓
⤷ Start Trial
|
